𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Possible role for chlorpheniramine in the treatment of l-DOPA induced dyskinesia in Parkinson’s disease

✍ Scribed by Karamanakos, Petros N. ;Pappas, Periklis ;Marselos, Marios

Publisher
Springer
Year
2007
Tongue
Dutch
Weight
107 KB
Volume
30
Category
Article
ISSN
1573-739X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Idazoxan, an alpha-2 antagonist, and L-D
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease
✍ O. Rascol; I. Arnulf; H. Peyro-Saint Paul; C. Brefel-Courbon; M. Vidailhet; C. T 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB

## Abstract Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopatherapy. Preclinical data in the 1‐methyl‐4‐phenyl‐1,2,3,6,‐tetrahydropyridine (MPTP) monkey suggest that alpha‐2 antagonists may reduce dihydroxyphenylalanine (L‐DOPA)‐induc